Which has stronger earnings and valuation, VKTX or CGEM?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is VKTX or CGEM more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -71.31% -65.35% Cullinan Therapeutics N/A -51.45% -47.64%

Does the media refer more to VKTX or CGEM?

In the previous week, Viking Therapeutics had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.34 beat Viking Therapeutics' score of 0.28 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACAD or CGEM?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 3 mentions for Cullinan Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Cullinan Therapeutics' score of 0.34 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, EWTX or CGEM?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is EWTX or CGEM more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -32.55% -31.04% Cullinan Therapeutics N/A -51.45% -47.64%

Does the media favor EWTX or CGEM?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Cullinan Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Cullinan Therapeutics' score of 0.34 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TNGX or CGEM more profitable?

Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Cullinan Therapeutics N/A -51.45% -47.64%

Does the media prefer TNGX or CGEM?

In the previous week, Tango Therapeutics had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Cullinan Therapeutics. Tango Therapeutics' average media sentiment score of 0.35 beat Cullinan Therapeutics' score of 0.34 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NAMS or CGEM?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 3 mentions for Cullinan Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.51 beat Cullinan Therapeutics' score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cullinan Therapeutics (CGEM) Competitors

$17.50 -0.19 (-1.07%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$17.63 +0.13 (+0.74%)

As of 04:32 AM Eastern

Compare

CGEM vs. VKTX, ACAD, EWTX, TNGX, and NAMS

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Viking Therapeutics presently has a consensus price target of $93.60, indicating a potential upside of 157.28%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 82.86%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Viking Therapeutics had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.34 beat Viking Therapeutics' score of 0.28 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Summary

Cullinan Therapeutics beats Viking Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Cullinan Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 3 mentions for Cullinan Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Cullinan Therapeutics' score of 0.34 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

ACADIA Pharmaceuticals currently has a consensus price target of $32.94, suggesting a potential upside of 31.29%. Cullinan Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 82.86%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ACADIA Pharmaceuticals beats Cullinan Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Edgewise Therapeutics presently has a consensus price target of $48.75, indicating a potential upside of 25.61%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 82.86%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Edgewise Therapeutics' return on equity of -32.55% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Cullinan Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Cullinan Therapeutics' score of 0.34 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Summary

Edgewise Therapeutics beats Cullinan Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Tango Therapeutics presently has a consensus target price of $42.15, suggesting a potential upside of 53.06%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 82.86%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Tango Therapeutics had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Cullinan Therapeutics. Tango Therapeutics' average media sentiment score of 0.35 beat Cullinan Therapeutics' score of 0.34 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tango Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.86	-$101.59M	-$0.83	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Summary

Tango Therapeutics beats Cullinan Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Cullinan Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

NewAmsterdam Pharma has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NewAmsterdam Pharma presently has a consensus target price of $49.42, suggesting a potential upside of 66.55%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 82.86%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

NewAmsterdam Pharma has higher revenue and earnings than Cullinan Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	154.15	-$203.82M	-$1.79	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 3 mentions for Cullinan Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.51 beat Cullinan Therapeutics' score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NewAmsterdam Pharma beats Cullinan Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.09B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-5.21	20.49	27.06	23.94
Price / Sales	N/A	300.33	514.89	90.87
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.53	7.92	10.66	6.14
Net Income	-$219.88M	$23.81M	$3.60B	$331.74M
7 Day Performance	-1.52%	-1.09%	-1.23%	-1.81%
1 Month Performance	16.43%	2.56%	1.11%	-1.44%
1 Year Performance	132.71%	42.16%	23.65%	16.33%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	2.4966 of 5 stars	$17.50 -1.1%	$32.00 +82.9%	+132.4%	$1.09B	N/A	N/A	30
VKTX Viking Therapeutics	3.1016 of 5 stars	$38.01 -0.3%	$93.60 +146.3%	+13.7%	$4.41B	N/A	N/A	20
ACAD ACADIA Pharmaceuticals	4.7931 of 5 stars	$25.36 -0.6%	$32.94 +29.9%	+11.2%	$4.34B	$1.07B	11.51	510
EWTX Edgewise Therapeutics	2.9623 of 5 stars	$39.88 -3.4%	$47.92 +20.1%	+186.6%	$4.28B	N/A	N/A	60	Analyst Forecast
TNGX Tango Therapeutics	2.5351 of 5 stars	$29.15 +2.8%	$41.50 +42.4%	+306.8%	$4.22B	$62.38M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. VKTX, ACAD, EWTX, TNGX, and NAMS

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Summary

How does Cullinan Therapeutics compare to Tango Therapeutics?

Summary

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. VKTX, ACAD, EWTX, TNGX, and NAMS

How does Cullinan Therapeutics compare to Viking Therapeutics?

Do analysts rate VKTX or CGEM?

Is VKTX or CGEM more profitable?

Do insiders and institutionals have more ownership in VKTX or CGEM?

Which has stronger earnings and valuation, VKTX or CGEM?

Does the media refer more to VKTX or CGEM?

Which has more volatility and risk, VKTX or CGEM?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Which has more volatility & risk, ACAD or CGEM?

Is ACAD or CGEM more profitable?

Do institutionals & insiders have more ownership in ACAD or CGEM?

Does the media favor ACAD or CGEM?

Which has preferable earnings & valuation, ACAD or CGEM?

Do analysts prefer ACAD or CGEM?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Do insiders & institutionals believe in EWTX or CGEM?

Do analysts recommend EWTX or CGEM?

Is EWTX or CGEM more profitable?

Does the media favor EWTX or CGEM?

Which has more volatility and risk, EWTX or CGEM?

Which has stronger earnings and valuation, EWTX or CGEM?

Summary

How does Cullinan Therapeutics compare to Tango Therapeutics?

Do analysts recommend TNGX or CGEM?

Does the media prefer TNGX or CGEM?

Is TNGX or CGEM more profitable?

Which has more volatility & risk, TNGX or CGEM?

Do insiders and institutionals hold more shares of TNGX or CGEM?

Which has better valuation & earnings, TNGX or CGEM?

Summary

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Is NAMS or CGEM more profitable?

Which has more volatility & risk, NAMS or CGEM?

Do insiders & institutionals hold more shares of NAMS or CGEM?

Do analysts rate NAMS or CGEM?

Which has stronger earnings & valuation, NAMS or CGEM?

Does the media prefer NAMS or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools